The BLA approval is supported by data from the COBLT study, FDA dockets and public information, and from a RegeneCyte observational database.

(HealthDay News) — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov. 14 in ...

(HealthDay News) — Based on the current trajectory, overweight and obesity will continue increasing in the United States up to 2050, according to a study published online Nov. 14 in The Lancet.

Maternal vaccination two to three or three to four weeks before delivery linked to lower cord:maternal transfer ratios versus at least five weeks ...

Seventy-six items achieved consensus, including indications for LDOM versus topical minoxidil, dosing for adults and teens, contraindications ...

Miplyffa was approved in September 2024 based on data from a clinical trial that showed arimoclomol plus miglustat slowed NPC disease progression.

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Risk increased with worsening CKD stage with denosumab versus bisphosphonates; highest risk seen for dialysis-dependent CKD, CKD-mineral and bone disorder ...

(HealthDay News) — Colchicine fails to improve knee pain, function, or size of synovial effusions with painful knee osteoarthritis (OA), according to a study presented at the annual meeting of the ...

(HealthDay News) — Spinal cord stimulation (SCS) for treatment of chronic pain in the back and/or lower extremities is associated with greater improvements in pain compared with conventional medical ...

In three databases, 4.5, 6.0, and 6.2 percent of medically attended RSV patients experienced 28-day all-cause hospitalization ...

Topline results were announced from a phase 3 trial evaluating linerixibat for the treatment of cholestatic pruritus in patients with primary biliary cholangitis (PBC).